The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.
The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown ...
2d
Zacks.com on MSNPharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPDEli Lilly LLY won a long-awaited FDA approval for its Alzheimer's disease (AD) drug, donanemab, to be sold under the brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results